ClinicalTrials.gg
CompletedNCT00719472RATEUpdated May 15, 2017Results posted

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)

A Phase 3 interventional study of Rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) in Non-Hodgkin's Lymphoma, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-15.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
451
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
11th of 171
451 · median 38
Started
2008
with 6 others
Phase 3
29 of 178
none open now
Registered
91st of 178
by date

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 11th largest by enrollment of the 171 interventional ones that give a count, is one of 7 that started in 2008, is one of 29 in phase 3, and was the 91st registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This was a prospective, open-label, Phase III, multicenter, single-arm trial designed to assess the safety, pharmacokinetics, and pharmacodynamics of an alternative dosing rate of rituximab in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) and follicular non-Hodgkin lymphoma (NHL).

03

Conditions studied

  • Non-Hodgkin's Lymphoma

Keywords

  • Follicular NHL
  • NHL
  • Large B-Cell NHL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Age ≥ 18 years
  • Patients with previously untreated diffuse large B-cell lymphoma (DLBCL) who are scheduled to receive rituximab 375 mg/m\^2 plus CHOP (cyclophosphamide, hydroxydaunorubicin [also called doxorubicin or adriamycin], Oncovin [vincristine], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-Hodgkin lymphoma (NHL) who are scheduled to receive rituximab 375 mg/m\^2 plus CVP (cyclophosphamide, vincristine, prednisolone) chemotherapy
  • (ECOG) performance status 0-2

Exclusion criteria

Exclusion Criteria:

* cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), (NYHA) Classification Grade II or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to Day 1, or NYHA Grade II or greater peripheral vascular disease on Day 1 (first day of treatment)

Patients who meet any of the following criteria will be excluded from further study participation after Cycle 1:

  • Circulating lymphocyte count > 5,000/μL before the Cycle 2 rituximab infusion
  • Development of a serious and/or Grade 3 or 4 adverse event during Cycle 1 judged by the investigator to be related to the rituximab infusion
  • Prior premedication with additional other than the prednisone included in the chemotherapy regimens
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
451 participants (actual)

Study arms

  • Experimental
    Rituximab 375 mg/m^2

    Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \[doxorubicin\], Oncovin \[vincristine\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.

    Drug: Rituximab · Drug: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) · Drug: CVP (cyclophosphamide, vincristine, prednisone) · Drug: Analgesic/antipyretic and antihistamine drugs

Interventions

  • During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.

  • Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.

  • DrugCVP (cyclophosphamide, vincristine, prednisone)

    Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.

  • DrugAnalgesic/antipyretic and antihistamine drugs

    An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2

    The percentage of patients who developed Grade 3 or 4 IRRs resulting from faster infusion of rituximab at Cycle 2 was assessed in patients who had previously received rituximab at the standard infusion rate without experiencing a Grade 3 or 4 IRR at Cycle 1. IRRs were a predefined list of Medical Dictionary for Regulatory Activities (MedDRA) terms for infusion-related adverse events occurring on the day of and/or the day after rituximab infusion. The list of IRR terms was compiled based on IRRs observed in the present and previous studies in which rituximab was infused at the standard rate.

    Time frame: Days 1 and 2 of Cycle 2

Secondary outcomes

  1. Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1

    Time frame: Cycle 1

  2. Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)

    Time frame: Cycle 2 through Cycle 6 or 8 (end of study)

  3. Duration of Rituximab Infusion Including Dose Interruption Times

    The median duration of the rituximab infusion on Day 1 of each cycle, including the duration of dose interruptions, is reported.

    Time frame: Day 1 of each of Cycles 1 to 6 or 8

  4. Maximum Serum Concentration (Cmax) of Rituximab Post-dose at the First Alternative Dosing Rate (Cycle 2) and the Last Cycle (Either Cycle 6 or 8)

    Serum samples for rituximab pharmacokinetic analysis were taken pre-dose (within 15 minutes before rituximab infusion) and post-dose (within 15 minutes after the end of the rituximab infusion) after the first faster infusion (Cycle 2) and after the last infusion (either Cycle 6 or 8). An enzyme-linked immunosorbent assay (ELISA) was used to measure rituximab levels in the serum samples.

    Time frame: Day 1 of Cycles 2 and either 6 or 8 (last cycle)

  5. Percentage of Patients Who Had Undetectable Levels of CD19+ Lymphocytes at Cycle 2 and Either Cycle 6 or 8 (Last Cycle)

    Serum samples for measurement of CD19+ lymphocytes were taken pre-dose (within 15 minutes before rituximab infusion). CD19+ lymphocyte counts were measured by flow cytometry using a fluorescent-activated cell sorter (FACS).

    Time frame: Day 1 of Cycle 2 and either Cycle 6 or 8 (last cycle)

07

Results

Posted Jun 26, 2012

Participant flow

Enrolled in Study
Participant flow — Enrolled in Study
MilestoneRituximab 375 mg/m^2
Started451
Completed425
Not completed26
Withdrew: Physician decision to withdraw patient1
Withdrew: Subject decision to withdraw8
Withdrew: Various reasons17
Received Cycle 1 Treatment
Participant flow — Received Cycle 1 Treatment
MilestoneRituximab 375 mg/m^2
Started425
Completed372
Not completed53
Withdrew: Adverse event8
Withdrew: Death5
Withdrew: Eligibility criteria for cycle 2 not met11
Withdrew: Physician decision to withdraw patient7
Withdrew: Subject decision to withdraw9
Withdrew: Various reasons13
Received Cycle 2 Treatment
Participant flow — Received Cycle 2 Treatment
MilestoneRituximab 375 mg/m^2
Started372
Completed304
Not completed68
Withdrew: Adverse event12
Withdrew: Death6
Withdrew: Disease progression3
Withdrew: Lost to follow-up3
Withdrew: Physician decision to withdraw patient13
Withdrew: Subject decision to withdraw6
Withdrew: Various reasons25

Outcome measures

PrimaryPercentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2

The percentage of patients who developed Grade 3 or 4 IRRs resulting from faster infusion of rituximab at Cycle 2 was assessed in patients who had previously received rituximab at the standard infusion rate without experiencing a Grade 3 or 4 IRR at Cycle 1. IRRs were a predefined list of Medical Dictionary for Regulatory Activities (MedDRA) terms for infusion-related adverse events occurring on the day of and/or the day after rituximab infusion. The list of IRR terms was compiled based on IRRs observed in the present and previous studies in which rituximab was infused at the standard rate.

Time frame:
Days 1 and 2 of Cycle 2
Reported as:
Number · Percentage of participants
Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2
Percentage of participantsRituximab 375 mg/m^2
Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 21.1 (0.3 to 2.8)
SecondaryPercentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1
Time frame:
Cycle 1
Reported as:
Number · Percentage of participants
Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1
Percentage of participantsRituximab 375 mg/m^2
Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 191.8
SecondaryPercentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)
Time frame:
Cycle 2 through Cycle 6 or 8 (end of study)
Reported as:
Number · Percentage of participants
Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)
Percentage of participantsRituximab 375 mg/m^2
Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)98.6
SecondaryDuration of Rituximab Infusion Including Dose Interruption Times

The median duration of the rituximab infusion on Day 1 of each cycle, including the duration of dose interruptions, is reported.

Time frame:
Day 1 of each of Cycles 1 to 6 or 8
Reported as:
Median · Minutes
Duration of Rituximab Infusion Including Dose Interruption Times
MinutesRituximab 375 mg/m^2
Cycle 1 (n=362)245 (225 to 273)
Cycle 2 (n=363)91 (90 to 98)
Cycle 3 (n=344)91 (90 to 98)
Cycle 4 (n=329)91 (90 to 96)
Cycle 5 (n=312)91 (90 to 95)
Cycle 6 (n=303)91 (90 to 96)
Cycle 7 (n=59)91 (90 to 95)
Cycle 8 (n=59)91 (90 to 95)
SecondaryMaximum Serum Concentration (Cmax) of Rituximab Post-dose at the First Alternative Dosing Rate (Cycle 2) and the Last Cycle (Either Cycle 6 or 8)

Serum samples for rituximab pharmacokinetic analysis were taken pre-dose (within 15 minutes before rituximab infusion) and post-dose (within 15 minutes after the end of the rituximab infusion) after the first faster infusion (Cycle 2) and after the last infusion (either Cycle 6 or 8). An enzyme-linked immunosorbent assay (ELISA) was used to measure rituximab levels in the serum samples.

Time frame:
Day 1 of Cycles 2 and either 6 or 8 (last cycle)
Reported as:
Mean · µg/mL
Maximum Serum Concentration (Cmax) of Rituximab Post-dose at the First Alternative Dosing Rate (Cycle 2) and the Last Cycle (Either Cycle 6 or 8)
µg/mLRituximab 375 mg/m^2
Cycle 2 (n=335)228.0 ± 63.7
Cycle 6 (n=238)275.0 ± 71.5
Cycle 8 (n=36)299.0 ± 90.6
SecondaryPercentage of Patients Who Had Undetectable Levels of CD19+ Lymphocytes at Cycle 2 and Either Cycle 6 or 8 (Last Cycle)

Serum samples for measurement of CD19+ lymphocytes were taken pre-dose (within 15 minutes before rituximab infusion). CD19+ lymphocyte counts were measured by flow cytometry using a fluorescent-activated cell sorter (FACS).

Time frame:
Day 1 of Cycle 2 and either Cycle 6 or 8 (last cycle)
Reported as:
Number · Percentage of participants
Percentage of Patients Who Had Undetectable Levels of CD19+ Lymphocytes at Cycle 2 and Either Cycle 6 or 8 (Last Cycle)
Percentage of participantsRituximab 375 mg/m^2
Cycle 2 (n=338)50.5 ± 24
Cycle 6 (n=240)68.3 ± 4
Cycle 8 (n=32)87.5 ± 0

Adverse events

Collected over Adverse events and serious adverse events were recorded from the start of study treatment until 30 days following the last administration of study treatment or at study discontinuation/early termination, whichever occurred earlier.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab 375 mg/m^2—107/425 (25.2%)421/425 (99.1%)
Most frequent serious events
Showing 10 of 88
Most frequent serious events
EventRituximab 375 mg/m^2
Febrile neutropeniaBlood and lymphatic system disorders33/425
DehydrationMetabolism and nutrition disorders12/425
NeutropeniaBlood and lymphatic system disorders10/425
PancytopeniaBlood and lymphatic system disorders7/425
PneumoniaInfections and infestations7/425
Abdominal painGastrointestinal disorders6/425
AnaemiaBlood and lymphatic system disorders5/425
SepsisInfections and infestations5/425
Cardiac failure congestiveCardiac disorders3/425
Atrial fibrillationCardiac disorders3/425
Most frequent other events
Showing 10 of 50
Most frequent other events
EventRituximab 375 mg/m^2
FatigueGeneral disorders227/425
NauseaGastrointestinal disorders202/425
AlopeciaSkin and subcutaneous tissue disorders169/425
ConstipationGastrointestinal disorders142/425
NeutropeniaBlood and lymphatic system disorders135/425
AnaemiaBlood and lymphatic system disorders100/425
InsomniaPsychiatric disorders100/425
DiarrhoeaGastrointestinal disorders99/425
Neuropathy peripheralNervous system disorders99/425
HeadacheNervous system disorders75/425

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rituximab 375 mg/m^2
Mean62.7 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab 375 mg/m^2
Female191
Male234
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2008
First posted
Jul 21, 2008
Start
Jul 2008
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Jun 26, 2012
Last update
May 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00719472
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jul 21, 2008
Start date
Jul 2008
Primary completion
May 2011
Completion
May 2011
Results posted
Jun 26, 2012
Last update
May 15, 2017

Study contacts

Deborah Hurst, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion